As smoking and smoking-related cancers decline in many regions, concern over the prevalence of lung cancer in those who have never smoked is growing. Rare germline variants of the EGFR gene — in ...

Scientists have discovered a powerful gene-targeting system in viruses. Billions of years old, VIPR seems to predate CRISPR and may be even more effective. By Carl Zimmer Over the past decade, the ...

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and Tianjin Medical University General Hospital have developed a bioinspired lipid nanoparticle ...

Pitney Bowes has commenced cash tender offers to purchase up to $50 million in aggregate principal amount of two outstanding debt securities as the company looks to retire a portion of its ...

Pitney Bowes (PBI) on Thursday launched tender offers to repurchase as much as $50 million in principal amount of two series of outstanding notes, using cash on hand to reduce its long-term debt. The ...

Modern music fans might not know too much about the work of Gene Pitney, who passed away in 2006. He was a standout songwriter and a thrilling performer, both of his own songs and of those written by ...

A Cambridge, Massachusetts biotechnology company dosed the first child in the world to receive an experimental gene therapy targeting GJB2 — the single most common genetic cause of childhood deafness ...

Rose covers disability and mental health, and she helps write STAT’s daily Morning Rounds newsletter. Confidential tips can be sent to Rose on Signal at rosebroderick.11. Two years ago, scientists ...

Pitney Bowes CEO Kurt Wolf joins 'Mad Money' host Jim Cramer to talk quarterly results, growth over the past year, presort services, and more. Got a confidential news tip? We want to hear from you.

Pioneering gene-editing treatments are already in clinical use, saving lives and easing the pain of devastating genetic diseases. However, the growing number of patients receiving these treatments ...

A new gene-editing company emerged from stealth on Tuesday with $230 million in committed financing, a reverse merger with a defunct oncology biotech, and a lead drug candidate licensed from a Chinese ...